Moving Beyond the PSA Debate

Hosted by the Prostate Cancer Foundation, this recent roundtable discussion among top experts addressed the growing controversy around PSA testing in men and provided clarity around what is currently the best available first-use tool in the process of diagnosing prostate cancer. The panel discussed who should be getting the PSA test, and what men and their physicians should know about using and interpreting results. The panel also previewed promising blood and urine tests still in development that may ultimately replace PSA testing and lead to more targeted treatment of aggressive prostate cancers.

Moving Beyond the PSA Debate, Part 1 from PCF on Vimeo.

Moving Beyond the PSA Debate, Part 2 from PCF on Vimeo.

Moving Beyond the PSA Debate, Part 3 from PCF on Vimeo.

Background
With research divided on the value of PSA testing, many men and their physicians are unclear on when or whether to get tested, and how they can protect their health. Experts estimate that overtreatment of prostate cancer costs $3 billion each year in the United States and takes a significant toll on men who experience side-effects from treatment. As our nation looks to reduce costs and improve the delivery of healthcare, leaders in the prostate cancer field are working to find ways to “overtreat less, and cure more” and are looking to genetics-, blood- and urine- based testing to replace PSA testing. Sustained research funding is critical to bringing these targeted tests to men and their physicians.